Pattern Pharma is an North American immunotherapy company whose PAR-1 product systemically activates the innate immune system (dendritic cells, macrophages and NK cells) to fight infectious diseases and cancers.  PAR-1 is newly patent-protected and is the next generation of a product which earlier received regulatory approval in an ex-US jurisdiction, where it has proven safe & efficacious during widespread use on patients in several indications. Pattern’s focus is on leveraging the large body of existing data and experience in order to obtain regulatory approvals for PAR-1 in the US, Europe, Asia and other key markets.